Max Robotics — Global Service Robot Directory + US Certification

About

Sara Kim is a pioneering translational researcher whose work bridges rare cancer biology and personalized medicine. Her most impactful contribution is the development of a personalized drug-screening platform using Drosophila (fruit fly) models, which has enabled real-time identification of effective combination therapies for individual patients with difficult-to-treat cancers. Her landmark 2019 study (107 citations) demonstrated the power of this approach by identifying trametinib plus zoledronate as a successful treatment for a patient with KRAS-mutant metastatic colorectal cancer, achieving a strong partial response lasting 11 months. She further validated this platform in a 2021 study (38 citations) for adenoid cystic carcinoma, a rare salivary gland cancer with limited treatment options. Kim’s work represents a paradigm shift from standard clinical trials to "N-of-1" personalized therapy, offering hope for patients with rare or genomically complex tumors. Additionally, she has contributed to gynecologic surgery outcomes, authoring a 2022 review on preventing vaginal cuff dehiscence after minimally invasive hysterectomy. Her innovative integration of model organisms into clinical decision-making has established her as a leader in precision oncology.